Publikationen 2017


Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017 Feb;76(2):422-426.

Riemekasten G, et al. Digitale Ulzerationen bei systemischer Sklerose : Eine Versorgungsforschungsstudie über den Einsatz von Bosentan und anderen vasoaktiven Therapien [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies]. Z Rheumatol. 2017 Apr;76(3):228-237. German. doi: 10.1007/s00393-016-0177-0.

Herrick AL, ... Riemekasten G, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 Jul;76(7):1207-1218. doi: 10.1136/annrheumdis-2016-210503. Epub 2017 Feb 10

Cabral-Marques O, ... Riemekasten G, et al. Human CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN-γ. J Allergy Clin Immunol. 2017 Mar;139(3):900-912.e7

Klapa S, Meyne J, Kähler W, Tillmans F, Werr H, Binder A, Koch A. Decompression illness with hypovolemic shock and neurological failure symptoms after two risky dives: a case report.Physiol Rep. 2017 Mar;5(6). pii: e13094. doi: 10.14814/phy2.13094.

Kowal-Bielecka O, ... Riemekasten G, et al. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study.  Rheumatology (Oxford). 2017 May 1;56(5):844-852. doi: 10.1093/rheumatology/kew499

Friedrich S, ... Riemekasten G, et al. Disturbed microcirculation in the hands of patients with systemic sclerosis detected by fluorescence optical imaging: a pilot study.Arthritis Res Ther. 2017 May 8;19(1):87. doi: 10.1186/s13075-017-1300-6.

López-Isac E, ... Riemekasten G, et al. Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort. Arthritis Rheumatol. 2017 Jun;69(6):1337-1338. doi: 10.1002/art.40058. Epub 2017 May 9

Carreira PE, ... Riemekasten G, et al. and EUSTAR co-authors.Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis.Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):114-121. Epub 2017 Jun 20.  

Bossini-Castillo L, ... Riemekasten G, et al. An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.J Rheumatol. 2017 Oct;44(10):1453-1457. doi: 10.3899/jrheum.161369. Epub 2017 Jul 1.

Elhai M, ... Riemekasten G, et al. and the EUSTAR group. Mapping and predicting mortality from systemic sclerosis.Ann Rheum Dis. 2017 Nov;76(11):1897-1905. doi: 1136/annrheumdis-2017-211448. Epub 2017 Aug 23.

Rose T, ... Riemekasten G, et al. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study.Rheumatology (Oxford). 2017 Sep 1;56(9):1618-1626. doi: 10.1093/rheumatology/kex220

Johnson SR, ... Riemekasten G, et al. There is a need for new systemic sclerosis subset criteria. A content analytic approach.Scand J Rheumatol. 2018 Jan;47(1):62-70. doi: 10.1080/03009742.2017.1299793. Epub 2017 Oct 9. 

Khanna D, ... Riemekasten G, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24. 

Lüders S, ... Riemekasten G, et al. Detection of severe digital vasculopathy in systemic sclerosis by colour Dopplersonography is associated with digital ulcers.Rheumatology (Oxford). 2017 Nov 1;56(11):1865-1873. doi: 10.1093/rheumatology/kex045. 

Denton CP, ... Riemekasten G, et al. Raynaud Study Investigators. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242.

Reviews, Letters, Reports, etc.